Clinical Trial Update: Multicenter Study of CAOMECS Transplantation to Patients With Total Limbal Stem Cell Deficiency [Phase 3]

View source ↗

Summary

A Phase 3 multicenter trial evaluating CAOMECS transplantation for total limbal stem cell deficiency has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Limbal Stem Cell Deficiency

Drugs mentioned

• CAOMECS transplantation (Cultured autologous oral mucosal epithelial cell sheet (CAOMECS))

Snippet

Sponsor: CellSeed France S.A.R.L. | Conditions: Limbal Stem Cell Deficiency | Phase 3 | Status: WITHDRAWN